023910 — Dai Han Pharm Co Balance Sheet
0.000.00%
- KR₩173bn
- KR₩87bn
- KR₩204bn
- 87
- 82
- 56
- 91
Annual balance sheet for Dai Han Pharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Annual Audited Accounts | Annual Audited Accounts | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 67,600 | 96,415 | 97,607 | 104,359 | 77,237 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 30,188 | 30,384 | 33,264 | 31,878 | 33,309 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 121,684 | 147,539 | 155,886 | 159,905 | 137,366 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 113,396 | 113,831 | 113,236 | 125,853 | 134,441 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 253,090 | 272,542 | 276,980 | 294,252 | 324,411 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 39,224 | 46,119 | 42,686 | 41,300 | 42,644 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 71,166 | 69,734 | 51,582 | 46,278 | 48,418 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 181,923 | 202,808 | 225,398 | 247,974 | 275,994 |
| Total Liabilities & Shareholders' Equity | 253,090 | 272,542 | 276,980 | 294,252 | 324,411 |
| Total Common Shares Outstanding |